#USA #Hamilton #Ac-225 #AtomVie #IONETIX

AtomVie Global Radiopharma and Ionetix Corporation Collaboration

On December 18, 2025, AtomVie Global Radiopharma (AtomVie) announced a pivotal supply agreement with Ionetix Corporation, aimed at enhancing the production of radiopharmaceuticals. This strategic partnership focuses on providing clinical-grade Ac-225, an alpha-emitting radioisotope essential for various therapeutic applications.

AtomVie, recognized as a leading global Contract Development and Manufacturing Organization (CDMO) for radiopharmaceuticals, is dedicated to ensuring that their partners have reliable access to this critical isotope. The agreement comes at a time when AtomVie is preparing to launch a new state-of-the-art radiopharmaceutical manufacturing facility in Hamilton, Ontario, in the first quarter of 2026. The increased demand for therapeutic isotopes necessitates a dependable supply chain to support clinical development from research stages to commercialization.

Bruno Paquin, CEO of AtomVie, emphasized the significance of this collaboration: “The reliable access to high-quality alpha-emitting isotopes like Ac-225 is essential for the next generation of targeted radiopharmaceuticals. Our partnership with Ionetix strengthens our capacity to support clients developing innovative alpha therapies while ensuring the integrity of the clinical supply chain.” This partnership not only enhances AtomVie’s service portfolio but also solidifies its position in the rapidly advancing sector of radionuclide therapies.

Ionetix, a leader in cyclotron technology and isotope production, brings significant expertise to the table. They will supply the cGMP-grade Ac-225 to AtomVie, thereby facilitating a scalable and reliable pathway for companies working on promising alpha therapies. David Eve, Vice President of Medical Affairs at Ionetix, remarked, “We are proud to partner with AtomVie at a time when the field of targeted radiopharmaceuticals is thriving. By providing Ac-225 for clinical use, we help create a more reliable and scalable pathway for companies striving to bring innovative alpha therapies to patients.”

The partnership is timely, considering the mounting global demand for radiopharmaceuticals. By ensuring consistent access to high-quality isotopes, AtomVie and Ionetix are positioned to meet the increasing requirements of their clients while advancing the innovation of radiopharmaceuticals.

About AtomVie Global Radiopharma

AtomVie is a leading CDMO specializing in GMP-compliant manufacturing and global distribution of clinical and commercial radiopharmaceuticals. They offer a comprehensive range of scientific, technical, regulatory, quality, and logistical services tailored to the development of radiopharmaceuticals, spanning from clinical studies through to commercial markets. Currently, AtomVie provides services to international clients conducting clinical studies in over 28 countries.

The company is investing in a new cutting-edge facility that measures 72,300 square feet, with plans for operational readiness in early 2026. For more information, visit AtomVie's website.

About Ionetix

Ionetix is at the forefront of cyclotron technology and radioisotope manufacturing, specializing in innovative solutions that provide access to rare isotopes for both diagnostic and therapeutic radiopharmaceuticals. They provide high-purity Ac-225 and At-211 for directed alpha therapies, supported by a robust distribution network, contract manufacturing services, and specialized logistics to enable global access.

For inquiries, contact:

• - Tina Chainani

Business Development Manager
Email: [email protected]

• - David Eve

Vice President of Medical Affairs
Email: [email protected]